Physical forms of an inhibitor of prc2

Abstract

The present disclosure relates to physical forms of a PRC2 inhibitor compound, pharmaceutical compositions comprising the physical forms of the compound, and methods of treating subjects having cancer by administering the physical forms, or a pharmaceutical composition comprising one or more of the physical forms, to the subject.

Dependencies are inferred from the claim text.